What Dalmadorm Mite Treats: Main Uses and Benefits

Dalmadorm Mite is applied across specific therapeutic domains to provide supportive relief for sleep disturbances. It is commonly used for managing symptoms that interfere with daily comfort, specifically in the symptomatic management of insomnia characterized by specific manifestations.

The primary symptoms addressed include difficulty falling asleep, fragmented sleep due to frequent nocturnal awakenings, and unrefreshing sleep quality. This medication is relevant across conditions presenting with acute episodes or episodic manifestations of sleeplessness.

Support for Acute and Situational Sleeplessness

This application involves conditions marked by periods of heightened symptoms, such as those driven by situational or transient stressors. It may assist patients during episodes of heightened discomfort by providing supportive relief when symptoms interfere with routine activities. It contributes to easing the overall symptom load by offering symptomatic assistance.

Quick Fact: Relevant for Symptomatic Relief in Sleep Disruption

Dalmadorm Mite is considered relevant when supportive symptom management is appropriate for the management of symptoms that create noticeable physiological strain.

Regulatory References

1. DailyMed (FDA) overview of Flurazepam Hydrochloride Capsules

Eligibility Map: Who can and cannot use Dalmadorm Mite — Official Regulatory Information

The official eligibility criteria for Dalmadorm Mite (Flurazepam) are defined by regulatory authorities through specific population categories that must use the medicine, those for whom use is restricted, and those for whom use is absolutely prohibited.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults for the short-term treatment of insomnia.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Flurazepam or other benzodiazepines.
	Pregnant women and individuals with severe respiratory depression.
	Patients with severe hepatic insufficiency, myasthenia gravis, or sleep apnoea syndrome.
Age-related eligibility rules	Use in pediatric patients (under 15 years) is not established and not currently recommended.
	Older adults require a lower, restricted initial dose due to increased sensitivity and risk of adverse central nervous system effects.
Condition-specific eligibility rules	Use requires caution in patients with impaired renal or hepatic function (non-severe) and those with chronic pulmonary insufficiency.
Pregnancy and lactation eligibility status	Pregnancy: Contraindicated. Lactation: Not recommended.

This framework dictates that use is permitted only for adults outside of these prohibited or restricted populations, requiring strict adherence to limitations concerning age, organ function, and underlying conditions.

Interactions with other medicines and products

The official regulatory profile for Dalmadorm Mite (Flurazepam) defines several mandatory constraints related to co-administration with other substances.

Contraindicated Combinations and Pharmacodynamic Risks

The co-administration of this medicine with Opioids is subject to regulatory restriction, owing to the documented risk of profound sedation, respiratory depression, and coma. This pharmacodynamic interaction represents an additive effect on the central nervous system (CNS). This additive CNS effect is also observed with alcohol and other CNS depressants, including certain antihistamines and sedative-hypnotics. Furthermore, the use of Flurazepam is formally contraindicated during pregnancy.

Metabolic and Exposure Alterations

The drug’s exposure is significantly affected by substances that alter hepatic metabolism. CYP inhibitors such as Cimetidine can increase the plasma concentration of Flurazepam and its active metabolite by reducing clearance. Conversely, CYP inducers, including Rifampin and certain herbal products like St John's Wort, can enhance Flurazepam metabolism, leading to reduced overall drug exposure.

Timing and Population Constraints

Due to the long half-life and the tendency for the active metabolite to accumulate during multiple-dose therapy, administration is restricted to circumstances where the patient can ensure a full night’s sleep (seven to eight hours). This accumulation risk is a key population-specific consideration for older adults, where slower metabolism increases the potential for next-day impairment.

Potentiation of GABA Inhibitory Signaling

The mechanism is defined by Flurazepam's role as a Positive Allosteric Modulator that targets the Benzodiazepine ( BZD) binding site on the inhibitory GABA A receptor complex. This molecular interaction enhances the receptor's sensitivity to the natural inhibitory neurotransmitter GABA, leading to an increased flux of chloride ions ( Cl^-) into the postsynaptic neuron.

---

Systemic Reduction of Neuronal Excitability

The resulting cellular hyperpolarization suppresses the firing rate of neurons throughout the central nervous system ( CNS), especially dampening activity in the Ascending Reticular Activating System ( ARAS). This reduction in widespread neuronal excitability functionally results in the physiological state of sedation and hypnosis (sleep state induction), alongside skeletal muscle relaxation.

---

Mechanism Constraints and Functional Tolerance

This allosteric mechanism is constrained by its absolute dependence on endogenous GABA being present and released. Chronic engagement of this potentiating action can lead to functional tolerance, where biological changes in the GABA A receptor complex reduce the functional modulation of the receptor over time.

How to Use Dalmadorm Mite (Flurazepam)

The administration of Dalmadorm Mite, which contains the active substance Flurazepam, follows specific parameters. The medication is designated for oral use only, typically provided as a solid capsule in strengths of 15 mg and 30 mg.

---

Dosing and Frequency Principles

Dosage is generally initiated at the lowest effective amount. For most adults, the usual starting dose is 15 mg or 30 mg. The medicine is administered once daily and must be taken immediately before going to bed. This timing is intended to allow the patient sufficient time to obtain a full night’s sleep of seven to eight hours before planned activity.

Duration and Special Population Rules

Flurazepam is indicated for short-term use. Treatment duration should be as brief as possible, usually limited to a maximum of four weeks, which includes any required tapering-off period. Continuation beyond this period necessitates a re-evaluation of the patient's condition.

Population-specific adjustments are applied: the initial nightly dose for older or debilitated patients must be limited to 15 mg. Similarly, a reduced dose of 15 mg is generally recommended for patients with hepatic or renal impairment.

Procedural Instructions

The capsule should be swallowed whole. If a dose is missed, a double dose should not be taken to compensate.

Dalmadorm Mite: Recent Clinical Evidence

Evidence for use in Insomnia

The research examined short-term Randomized Controlled Trials (RCTs) and controlled sleep laboratory studies. These studies research examined individuals experiencing insomnia, a condition characterized by fluctuating or episodic manifestations, and focused on specific sleep disturbances like difficulty falling asleep, frequent nocturnal awakenings, and early morning waking.

In these trials, researchers monitored several types of outcomes related to sleep. These included objective measures taken in a laboratory, such as Polysomnography (PSG), which tracks brain activity and other sleep parameters. Objective outcomes evaluated included the time it took participants to fall asleep (sleep latency), the total amount of time spent asleep (Total Sleep Time, TST), and the duration of waking periods after sleep onset. Studies also applied in research contexts involving fluctuating or unstable symptoms and collected patient-reported outcomes describing perceived discomfort and the quality of sleep.

In these short-term studies, findings were observed in some studies where participants described changes in sleep duration and quality compared to those receiving placebo. Studies report patterns related to the duration of sleep maintenance that were measured during the study period, which was evaluated in the studies examining sustained sleep. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.

Long-Term Evidence and Follow-up Patterns

The evidence available from well-controlled RCTs is focused on short-term use, typically for periods lasting up to four weeks. Studies observing responses over defined time intervals beyond this duration are more limited.

Evidence for continuous use over several months is limited, and the long-term effects are not fully established. Some studies have explored use for slightly longer periods in comparative trials, and these findings indicate data show patterns related to how individuals' sleep patterns evolved in the observed populations during the study period. Furthermore, studies monitored for temporary physiological imbalance after the medicine was stopped; findings describe patterns where a return or temporary worsening of the original sleep problem was observed in some studies upon abrupt discontinuation.

Evidence in Special Populations

Research has explored the use of this medicine in specific subgroups. The geriatric population (older adults) was evaluated in dedicated studies where research examined patterns related to accumulation. The results apply only to the populations studied, and research provided insight into short-term changes for its profile in this age group.

However, data for certain groups remain insufficient. For instance, children and adolescents were generally excluded from the primary clinical trials, and there is limited information for long-term outcomes in any subgroup.

Research Gaps and Uncertainty

Despite the existence of high-quality short-term RCTs, certain scientific limitations remain. Follow-up durations were limited in many of the key trials, meaning the certainty remains low regarding the patterns observed over many months or years.

The evidence quality varies across studies, and the long-term outcomes are not well characterized. Research gaps include limited information for long-term outcomes and how the cumulative effect of the active metabolite was studied for next-day alertness and functional measures. This evidence highlights what is known—and what is still uncertain—about the medicine's profile.

Common questions about Dalmadorm Mite (FAQ)

Q: What are the general differences between Dalmadorm Mite and similar medicines?

Official information indicates that the active ingredient in Dalmadorm Mite is categorized as a long-acting medicine. This is due to a primary active compound, a metabolite, that remains in the body for an extended time. This long-acting characteristic is designed to support sustained sedation throughout the night.

Q: Is Dalmadorm Mite considered a controlled substance by regulatory bodies?

Yes, regulatory bodies classify the active ingredient, Flurazepam, as a Schedule IV controlled substance. This designation is based on the potential for abuse, misuse, and the development of physical or psychological dependence. Official safety information includes warnings regarding the risks of addiction and withdrawal.

Q: Is Dalmadorm Mite known to cause next-day drowsiness or 'hangover effects'?

Official product information describes that next-day impairment, including drowsiness and dizziness, can occur as a potential side effect. These residual effects can affect alertness and motor coordination and may be associated with an increased risk of falling or accidents. The potential for this impairment is a key population-specific consideration.

Q: Can Dalmadorm Mite cause gastrointestinal side effects like nausea or stomach upset?

While general gastrointestinal issues are mentioned in official safety data, nausea and vomiting are specifically noted as potential symptoms of a rare but serious allergic reaction. If these symptoms occur alongside others like swelling or difficulty breathing, this indicates a serious adverse event described in official warnings.

Q: What are the signs of a severe allergic reaction to Dalmadorm Mite described in patient information leaflets?

According to official regulatory information, signs of a rare but severe allergic reaction (such as anaphylaxis or angioedema) may include trouble breathing, swelling of the throat or tongue, rash, and hives. Nausea and vomiting can also be associated with these serious events.

Q: Is it necessary to avoid alcohol completely while using Dalmadorm Mite?

Yes, regulatory guidance is explicit that this medicine should not be taken with alcohol. Alcohol is a central nervous system depressant and using it with this medicine increases the risk of serious adverse effects, such as profound sedation, respiratory depression, and coma.

Q: Does Dalmadorm Mite interact with common over-the-counter pain relievers or cold medicines?

Official safety information warns against combining this medicine with any other drugs that cause sleepiness, which can include many common over-the-counter (OTC) products. This is because the combined depressant effects can be additive and increase risks such as excessive drowsiness and impaired coordination. Official guidance emphasizes that other OTC medicines should be reviewed with a healthcare provider.

Q: How fast does the official literature say Dalmadorm Mite typically begins to work?

Official pharmacological data indicates that the medicine is rapidly absorbed into the body. Peak levels of the parent compound in the blood typically occur between 30 and 60 minutes after a single oral dose. This profile supports its use for difficulty falling asleep.

Q: How long does the effect of a standard dose of Dalmadorm Mite usually last?

The drug's efficacy has been objectively confirmed in short-term studies for maintaining sleep across at least 28 consecutive nights. The primary active metabolite has an extended half-life, which can range from 47 to 100 hours. This prolonged presence is consistent with the drug's long-acting profile, which is designed to support sustained sleep maintenance.

Q: What is the difference between Dalmadorm Mite and a regular-strength version of the drug?

The medicine is available in different strengths, such as 15 mg and 30 mg. The lower strength (e.g., 15 mg) is described in official prescribing information as the initial dose to be considered for certain populations, including older or debilitated adults, to minimize residual effects.

Q: Does Dalmadorm Mite contain ingredients like lactose, gluten, or common dyes?

Official product descriptions confirm that the inactive ingredients list generally includes anhydrous lactose, various coloring dyes, and gelatin. Due to the presence of inactive ingredients like lactose, patients with known sensitivities are advised to check the specific product label.

Q: What is the official guidance regarding Dalmadorm Mite and changes in mood or behavior?

Official safety data reports that abnormal thoughts and behaviors have been observed. These can include unusual excitement, confusion, agitation, hallucinations, and a worsening of existing depression or the emergence of suicidal ideation. Patients are advised to monitor for these changes.

Q: What is the general guidance on using Dalmadorm Mite with blood pressure medication?

Official labeling contains a general caution regarding drug-drug interactions. The official label specifies that a healthcare provider should be informed about all prescription medicines taken. This includes any medications used to manage conditions like high blood pressure.

Q: Does the medicine need to be taken with food, or can it be taken on an empty stomach?

Regulatory guidance specifies that the capsule must be taken immediately before going to bed. However, the official prescribing information does not provide specific instructions regarding whether the medicine must be taken with or without food for absorption. The focus is on the timing of administration.

Q: Is there a Black Box Warning or similar major safety caution associated with Dalmadorm Mite?

Yes, the regulatory labeling for this medicine includes a Boxed Warning, which is the strongest safety warning issued by the FDA. This warning emphasizes the serious risks associated with the co-administration of opioids, as well as the risks of abuse, dependence, and severe withdrawal reactions.

Official Storage and Disposal Requirements

The storage and disposal of Dalmadorm Mite, which contains flurazepam hydrochloride, must strictly follow regulatory guidance for maintaining product stability and securing a controlled substance.

Requirement Type	Official Condition
Temperature Range	Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Environment	Keep the medicine in a dry place and a safe place to prevent theft or misuse.
Child Safety	Mandatory to keep the product out of the reach of children.
Disposal	Unused or expired medication must be disposed of via a drug take-back program or by following specific official procedures for controlled substances; do not flush or place in household trash.

These rules define the required temperature, mandate protection from moisture, and establish secure storage and formal controlled-waste disposal protocols.